Latest Market News

Orora Limited has announced a 5-cent per share ordinary dividend for the six months ending December 2024, payable in April 2025. The dividend is unfranked and offers shareholders a Dividend Reinvestment Plan option.

Orora Limited reported a substantial half-year profit of A$907.6 million, propelled by the sale of its North America packaging business and strategic restructuring. The company also announced an unfranked interim dividend of 5 cents per share.

Origin Energy reported a solid half-year performance with statutory profit rising to $1.02 billion and underlying profit up 24% to $924 million, driven by strong LNG trading and APLNG operations. The company is advancing its renewable energy investments and technology platforms while maintaining dividend growth.

Origin Energy reported a robust half-year performance with statutory profit rising to $1.017 billion and an increased fully franked interim dividend, driven by strong Integrated Gas earnings despite softer Energy Markets and Octopus Energy results.

Origin Energy has announced a fully franked ordinary dividend of AUD 0.30 per share for the six months ending December 2024, signaling steady shareholder returns.

Origin Energy reported a robust half-year result for December 2024, with revenue up 10% and profit rising 2%, while accelerating investments in battery storage and renewables.

Treasury Wine Estates delivered a robust 1H25 performance driven by luxury brands Penfolds and DAOU, offsetting softness in its premium and commercial portfolios. Despite strong earnings growth, the company lowers its full-year EBITS guidance, highlighting ongoing market headwinds.

Treasury Wine Estates reports a robust first half of 2025, driven by luxury portfolio growth and DAOU integration, while premium segments face headwinds.

Treasury Wine Estates has announced a 20-cent per share dividend for the half-year ending December 2024, accompanied by a fully franked component and an active Dividend Reinvestment Plan.

Treasury Wine Estates has delivered a robust half-year performance with revenue climbing nearly 20% and profit surging 33%, driven by premiumisation and strategic acquisitions. The company also declared a higher interim dividend, signaling confidence in its growth trajectory.

Telix Pharmaceuticals has gained UK MHRA approval for Illuccix, its advanced prostate cancer PET imaging agent, promising to alleviate supply shortages and improve diagnostic accuracy across the UK.

Insurance Australia Group Limited has announced a quarterly distribution of AUD 1.5191 per Capital Note 3 security, partially franked at 60%, payable on March 17, 2025.